Anti-influenza A virus activity by Agrimonia pilosa and Galla rhois extract mixture
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Joo, Yong-Hyun | - |
dc.contributor.author | Lee, Yeong-Geun | - |
dc.contributor.author | Lim, Younghyun | - |
dc.contributor.author | Jeon, Hoyeon | - |
dc.contributor.author | Lee, In-Gu | - |
dc.contributor.author | Cho, Yong-Bin | - |
dc.contributor.author | Hong, So-Hee | - |
dc.contributor.author | Kim, Eui Ho | - |
dc.contributor.author | Choi, Soon Ho | - |
dc.contributor.author | Kim, Jung-Woong | - |
dc.contributor.author | Kang, Se Chan | - |
dc.contributor.author | Seo, Young-Jin | - |
dc.date.accessioned | 2022-11-18T09:40:07Z | - |
dc.date.available | 2022-11-18T09:40:07Z | - |
dc.date.issued | 2022-11 | - |
dc.identifier.issn | 0753-3322 | - |
dc.identifier.issn | 1950-6007 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/59099 | - |
dc.description.abstract | Influenza A virus (IAV) continues to threaten human health. To date, two classes of antiviral drugs have been approved to treat IAV infection, but the continuous emergence of the drug-resistant IAV mutant reinforces the need to develop new antiviral drugs. In this study, we aimed to investigate the anti-IAV activity of an aqueous mixture of Agrimonia pilosa and Galla rhois extracts (APRG64). We demonstrated that APRG64 significantly reduced the IAV-induced cytopathic effect, the transcription/expression of viral proteins, and the production of infectious viral particles. Among nine major components of APRG64, apigenin was identified as the main ingredient responsible for the anti-IAV activity. Interestingly, APRG64 and apigenin inhibited the cell attachment and entry of virus and polymerase activity. Importantly, intranasal administration of APRG64 or apigenin strongly reduced viral loads in the lungs of IAV-infected mice. Furthermore, oral administration of APRG64 significantly reduced the level of viral RNAs and the expression level of pro-inflammatory cytokines in the lungs, which protected mice from IAV-induced mortality. In conclusion, APRG64 could be an attractive antiviral drug to treat IAV infection. © 2022 The Authors | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier Masson s.r.l. | - |
dc.title | Anti-influenza A virus activity by Agrimonia pilosa and Galla rhois extract mixture | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.biopha.2022.113773 | - |
dc.identifier.bibliographicCitation | Biomedicine and Pharmacotherapy, v.155 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000870455600005 | - |
dc.identifier.scopusid | 2-s2.0-85139081208 | - |
dc.citation.title | Biomedicine and Pharmacotherapy | - |
dc.citation.volume | 155 | - |
dc.type.docType | Article | - |
dc.publisher.location | 프랑스 | - |
dc.subject.keywordAuthor | Antiviral drug | - |
dc.subject.keywordAuthor | Apigenin | - |
dc.subject.keywordAuthor | APRG64 | - |
dc.subject.keywordAuthor | Influenza A virus | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | APIGENIN | - |
dc.subject.keywordPlus | ANTIOXIDANT | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | FLAVONOIDS | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | PLANTS | - |
dc.subject.keywordPlus | L. | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.